-
Almost one-fifth of Medicare patients who were discharged from a hospital were rehospitalized within 30 days, and about a third were rehospitalized within 90 days. Most of these readmissions were not planned.
-
Everolimus is the newest oral kinase inhibitor approved for the treatment of advanced renal cell carcinoma.
-
The ACCORD trial has been newsworthy in the last several months primarily due to the early results of increased cardiovascular events associated with very tight glucose control.
-
The simultaneously obtained lead II and lead V1 rhythm strip seen above was interpreted as showing atrial fibrillation with a rapid ventricular response. Do you agree?
-
-
One of the most confusing areas in medicine, which spills over into obstetrics, is thrombophilia, and seemingly every year a new antibody affecting the clotting system emerges that causes worry. One of the worries involves a possible link with pre-eclampsia.
-
Arzoxifene is being developed by Eli Lilly and Co. to prevent bone loss and treat osteoporosis.
-
A review of any publication from 1960 to 2007 with the main outcome of time to fertility following oral contraceptive discontinuation was performed.
-
During the last two months an unusual number of papers were published which, while not having earth-shaking scientific value, should have some clinical impact.
-
Data from the Surveillance Epidemiology and End Results (SEER) registry have consistently demonstrated improved life expectancy for women with epithelial ovarian cancer every year since 1973.
